Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B

Clinical Transplantation

Volumn 19, Issue 3, 2005, Pages 321-326

  Nikolaidis, Nikolaos ^a,b   Vassiliadis, Themistoklis ^a   Giouleme, Olga ^a   Tziomalos, Konstantinos ^a   Grammatikos, Nikolaos ^a   Patsiaoura, Kalliopi ^a   Orfanou Koumerkeridou, Eleni ^a   Balaska, Aikaterini ^a   Eugenidis, Nikolaos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Breakthrough infection; Lamivudine resistance; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; NONHUMAN; PREOPERATIVE CARE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 19044393444     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00340.x     Document Type: Article

References (36)

1. De Jongh FE, Janssen HLA, De Man LA, Hop WCJ, Schalm SW, Van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992: 103: 1630.
2. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immunoglobulin. Hepatology 1998: 28: 585.
3. Pierce GA, Grahm WK, Kaufman HM Jr, Wolf JS. The United Network for Organ Sharing: 1984 to 1994. Transplant Proc 1996: 28: 12.
4. Keeffe EB. Summary of guidelines on organ allocation and patient listing for liver transplantation. Liver Transplant Surg 1998: 4 (Suppl. 1): S108.
5. Nevens F, Goubau P, Van Eyken P, Desmyter J, Desmet V, Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 1993: 13: 15.
6. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993: 104: 1116.
7. Perillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995: 109: 908.
8. Marcellin P, Giuily N, Loriot MA et al. Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis. J Viral Hepat 1997: 4 (Suppl. 1): 21.
9. Villeneuve J, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000: 31: 207.
10. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000: 33: 301.
11. Kapoor D, Guptan RC, Wakil S et al. Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis. J Hepatol 2000: 33: 308.
12. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001: 34: 411.
13. Fontana RJ, Keeffe EB, Carey W et al. for the National Institutes of Health. Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplant 2002: 8: 433.
14. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001: 34: 903.
15. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant 2000: 6: 429.
16. Steinmueller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002: 35: 1528.
17. Manolakopoulos S, Karatapanis S, Elefsiniotis J et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2003: 99: 57.
18. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995: 1: 7.
19. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and take over of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998: 2: 1711.
20. Melagari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998: 27: 628.
21. Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis virus infection in the liver transplant recipient. Gut 2000: 46: 107.
22. Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000: 119: 1382.
23. Nedjar S, Mitchell F, Biswas R. Simultaneous amplification and detection of specific hepatitis B virus and hepatitis C virus genomic sequences in serum samples. J Med Virol 1994: 42: 212.
24. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001: 33: 464.
25. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991: 32: 294.
26. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapia J. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994: 21: 656.
27. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants, and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991: 13: 627.
28. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian Trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001: 33: 424.
29. Fontana RJ, Hann HWL, Perillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002: 123: 719.
30. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003: 124: 91.
31. Weissberg JI, Andres LL, Smith CI et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984: 101: 613.
32. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997: 349: 20.
33. Yoshida EM, Ma MM, Davis JE et al. Post liver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long term follow up. Can J Gastroenterol 1998: 12: 125.
34. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000: 32: 129.
35. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001: 49: 436.
36. Mutimer D, Feraz-Neto BH, Harrison R et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001: 49: 860.